Nanomedicine for cancer patient‐centered care DOI Creative Commons
Carlo Sorrentino, Stefania L. Ciummo, Cristiano Fieni

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(11)

Published: Oct. 20, 2024

Abstract Cancer is a leading cause of morbidity and mortality worldwide, an increase in incidence estimated the next future, due to population aging, which requires development highly tolerable low‐toxicity cancer treatment strategies. The use nanotechnology tailor treatments according genetic immunophenotypic characteristics patient's tumor, allow its targeted release, can meet this need, improving efficacy minimizing side effects. Nanomedicine‐based approach for diagnosis rapidly evolving field. Several nanoformulations are currently clinical trials, some have been approved marketed. However, their large‐scale production still hindered by in‐depth debate involving ethics, intellectual property, safety health concerns, technical issues, costs. Here, we survey key approaches, with specific reference organ‐on chip technology, cutting‐edge tools, such as CRISPR/Cas9 genome editing, through nanosystems needs personalized diagnostics therapy patients. An update provided on nanopharmaceuticals marketed those undergoing trials. Finally, discuss emerging avenues field challenges be overcome transfer nano‐based precision oncology into daily life.

Language: Английский

Comprehensive proteomic analysis and multidimensional model construction of peritoneal metastasis in gastric cancer DOI
Xiangpan Li,

Jiatong Lu,

Fangfang Chen

et al.

Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217509 - 217509

Published: Feb. 1, 2025

Language: Английский

Citations

0
Nanocarriers for cutting-edge cancer immunotherapies DOI Creative Commons
Joyce Hu, Pooria Mohammadi Arvejeh,

S Bone

et al.

Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)

Published: April 15, 2025

Cancer immunotherapy aims to harness the body's own immune system for effective and long-lasting elimination of malignant neoplastic tissues. Owing advance in understanding cancer pathology immunology, many novel strategies enhancing immunological responses against various cancers have been successfully developed, some translated into excellent clinical outcomes. As one promising strategy next generation immunotherapies, activating multi-cellular network (MCN) within tumor microenvironment (TME) deploy multiple mechanisms action (MOAs) has attracted significant attention. To achieve this effectively safely, delivering or pleiotropic therapeutic cargoes targeted sites cancerous tissues, cells, intracellular organelles is critical, which numerous nanocarriers developed leveraged. In review, we first introduce payloads categorized according their predicted functions physicochemical structures forms. Then, nanocarriers, along with unique characteristics, properties, advantages, limitations, are introduced notable recent applications immunotherapy. Following discussions on targeting strategies, a summary each nanocarrier matching suitable provided comprehensive background information designing regimens.

Language: Английский

Citations

0
Regulation of the CD8⁺ T Cell and PDL1/PD1 Axis in Gastric Cancer: Unraveling the Molecular Landscape DOI
Yong Xin, Dong Mu, Hanyu Ni

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104750 - 104750

Published: April 1, 2025

Language: Английский

Citations

0
Nanomedicine for cancer patient‐centered care DOI Creative Commons
Carlo Sorrentino, Stefania L. Ciummo, Cristiano Fieni

et al.

MedComm, Journal Year: 2024, Volume and Issue: 5(11)

Published: Oct. 20, 2024

Abstract Cancer is a leading cause of morbidity and mortality worldwide, an increase in incidence estimated the next future, due to population aging, which requires development highly tolerable low‐toxicity cancer treatment strategies. The use nanotechnology tailor treatments according genetic immunophenotypic characteristics patient's tumor, allow its targeted release, can meet this need, improving efficacy minimizing side effects. Nanomedicine‐based approach for diagnosis rapidly evolving field. Several nanoformulations are currently clinical trials, some have been approved marketed. However, their large‐scale production still hindered by in‐depth debate involving ethics, intellectual property, safety health concerns, technical issues, costs. Here, we survey key approaches, with specific reference organ‐on chip technology, cutting‐edge tools, such as CRISPR/Cas9 genome editing, through nanosystems needs personalized diagnostics therapy patients. An update provided on nanopharmaceuticals marketed those undergoing trials. Finally, discuss emerging avenues field challenges be overcome transfer nano‐based precision oncology into daily life.

Language: Английский

Citations

2